HER2 is a bona fide driver gene in breast cancer [2-5], and HER2 amplification is the predictive marker and molecular target of anti-HER2 agents such as trastuzumab, pertuzumab or lapatinib [6]. The gene discussed is ERBB2; the disease is breast cancer.